Clinical Trial Update: A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis [Phase 3]

View source ↗

Summary

Phase 3 trial of avacopan (CCX168) in ANCA-associated vasculitis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Granulomatosis with Polyangiitis
• Microscopic Polyangiitis

Drugs mentioned

• Avacopan (avacopan)

Snippet

Sponsor: Amgen | Conditions: ANCA-Associated Vasculitis | Phase 3 | Status: COMPLETED | Results posted: 2022-09-09